Locus coeruleus imaging as a biomarker for noradrenergic dysfunction in neurodegenerative diseases

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Locus coeruleus imaging as a biomarker for noradrenergic dysfunction in neurodegenerative diseases. / Betts, Matthew J; Kirilina, Evgeniya; Otaduy, Maria C G; Ivanov, Dimo; Acosta-Cabronero, Julio; Callaghan, Martina F; Lambert, Christian; Cardenas-Blanco, Arturo; Pine, Kerrin; Passamonti, Luca; Loane, Clare; Keuken, Max C; Trujillo, Paula; Lüsebrink, Falk; Mattern, Hendrik; Liu, Kathy Y; Priovoulos, Nikos; Fliessbach, Klaus; Dahl, Martin J.; Maaß, Anne; Madelung, Christopher F; Meder, David; Ehrenberg, Alexander J; Speck, Oliver; Weiskopf, Nikolaus; Dolan, Raymond; Inglis, Ben; Tosun, Duygu; Morawski, Markus; Zucca, Fabio A; Siebner, Hartwig R.; Mather, Mara; Uludag, Kamil; Heinsen, Helmut; Poser, Benedikt A; Howard, Robert; Zecca, Luigi; Rowe, James B.; Grinberg, Lea T; Jacobs, Heidi I L; Düzel, Emrah; Hämmerer, Dorothea.

I: Brain, Bind 142, Nr. 9, 2019, s. 2558-2571.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Betts, MJ, Kirilina, E, Otaduy, MCG, Ivanov, D, Acosta-Cabronero, J, Callaghan, MF, Lambert, C, Cardenas-Blanco, A, Pine, K, Passamonti, L, Loane, C, Keuken, MC, Trujillo, P, Lüsebrink, F, Mattern, H, Liu, KY, Priovoulos, N, Fliessbach, K, Dahl, MJ, Maaß, A, Madelung, CF, Meder, D, Ehrenberg, AJ, Speck, O, Weiskopf, N, Dolan, R, Inglis, B, Tosun, D, Morawski, M, Zucca, FA, Siebner, HR, Mather, M, Uludag, K, Heinsen, H, Poser, BA, Howard, R, Zecca, L, Rowe, JB, Grinberg, LT, Jacobs, HIL, Düzel, E & Hämmerer, D 2019, 'Locus coeruleus imaging as a biomarker for noradrenergic dysfunction in neurodegenerative diseases', Brain, bind 142, nr. 9, s. 2558-2571. https://doi.org/10.1093/brain/awz193

APA

Betts, M. J., Kirilina, E., Otaduy, M. C. G., Ivanov, D., Acosta-Cabronero, J., Callaghan, M. F., Lambert, C., Cardenas-Blanco, A., Pine, K., Passamonti, L., Loane, C., Keuken, M. C., Trujillo, P., Lüsebrink, F., Mattern, H., Liu, K. Y., Priovoulos, N., Fliessbach, K., Dahl, M. J., ... Hämmerer, D. (2019). Locus coeruleus imaging as a biomarker for noradrenergic dysfunction in neurodegenerative diseases. Brain, 142(9), 2558-2571. https://doi.org/10.1093/brain/awz193

Vancouver

Betts MJ, Kirilina E, Otaduy MCG, Ivanov D, Acosta-Cabronero J, Callaghan MF o.a. Locus coeruleus imaging as a biomarker for noradrenergic dysfunction in neurodegenerative diseases. Brain. 2019;142(9):2558-2571. https://doi.org/10.1093/brain/awz193

Author

Betts, Matthew J ; Kirilina, Evgeniya ; Otaduy, Maria C G ; Ivanov, Dimo ; Acosta-Cabronero, Julio ; Callaghan, Martina F ; Lambert, Christian ; Cardenas-Blanco, Arturo ; Pine, Kerrin ; Passamonti, Luca ; Loane, Clare ; Keuken, Max C ; Trujillo, Paula ; Lüsebrink, Falk ; Mattern, Hendrik ; Liu, Kathy Y ; Priovoulos, Nikos ; Fliessbach, Klaus ; Dahl, Martin J. ; Maaß, Anne ; Madelung, Christopher F ; Meder, David ; Ehrenberg, Alexander J ; Speck, Oliver ; Weiskopf, Nikolaus ; Dolan, Raymond ; Inglis, Ben ; Tosun, Duygu ; Morawski, Markus ; Zucca, Fabio A ; Siebner, Hartwig R. ; Mather, Mara ; Uludag, Kamil ; Heinsen, Helmut ; Poser, Benedikt A ; Howard, Robert ; Zecca, Luigi ; Rowe, James B. ; Grinberg, Lea T ; Jacobs, Heidi I L ; Düzel, Emrah ; Hämmerer, Dorothea. / Locus coeruleus imaging as a biomarker for noradrenergic dysfunction in neurodegenerative diseases. I: Brain. 2019 ; Bind 142, Nr. 9. s. 2558-2571.

Bibtex

@article{d858fab01c9644c2916e39ee808bb5c6,
title = "Locus coeruleus imaging as a biomarker for noradrenergic dysfunction in neurodegenerative diseases",
abstract = "Pathological alterations to the locus coeruleus, the major source of noradrenaline in the brain, are histologically evident in early stages of neurodegenerative diseases. Novel MRI approaches now provide an opportunity to quantify structural features of the locus coeruleus in vivo during disease progression. In combination with neuropathological biomarkers, in vivo locus coeruleus imaging could help to understand the contribution of locus coeruleus neurodegeneration to clinical and pathological manifestations in Alzheimer's disease, atypical neurodegenerative dementias and Parkinson's disease. Moreover, as the functional sensitivity of the noradrenergic system is likely to change with disease progression, in vivo measures of locus coeruleus integrity could provide new pathophysiological insights into cognitive and behavioural symptoms. Locus coeruleus imaging also holds the promise to stratify patients into clinical trials according to noradrenergic dysfunction. In this article, we present a consensus on how non-invasive in vivo assessment of locus coeruleus integrity can be used for clinical research in neurodegenerative diseases. We outline the next steps for in vivo, post-mortem and clinical studies that can lay the groundwork to evaluate the potential of locus coeruleus imaging as a biomarker for neurodegenerative diseases.",
author = "Betts, {Matthew J} and Evgeniya Kirilina and Otaduy, {Maria C G} and Dimo Ivanov and Julio Acosta-Cabronero and Callaghan, {Martina F} and Christian Lambert and Arturo Cardenas-Blanco and Kerrin Pine and Luca Passamonti and Clare Loane and Keuken, {Max C} and Paula Trujillo and Falk L{\"u}sebrink and Hendrik Mattern and Liu, {Kathy Y} and Nikos Priovoulos and Klaus Fliessbach and Dahl, {Martin J.} and Anne Maa{\ss} and Madelung, {Christopher F} and David Meder and Ehrenberg, {Alexander J} and Oliver Speck and Nikolaus Weiskopf and Raymond Dolan and Ben Inglis and Duygu Tosun and Markus Morawski and Zucca, {Fabio A} and Siebner, {Hartwig R.} and Mara Mather and Kamil Uludag and Helmut Heinsen and Poser, {Benedikt A} and Robert Howard and Luigi Zecca and Rowe, {James B.} and Grinberg, {Lea T} and Jacobs, {Heidi I L} and Emrah D{\"u}zel and Dorothea H{\"a}mmerer",
year = "2019",
doi = "10.1093/brain/awz193",
language = "English",
volume = "142",
pages = "2558--2571",
journal = "Brain",
issn = "0006-8950",
publisher = "Oxford University Press",
number = "9",

}

RIS

TY - JOUR

T1 - Locus coeruleus imaging as a biomarker for noradrenergic dysfunction in neurodegenerative diseases

AU - Betts, Matthew J

AU - Kirilina, Evgeniya

AU - Otaduy, Maria C G

AU - Ivanov, Dimo

AU - Acosta-Cabronero, Julio

AU - Callaghan, Martina F

AU - Lambert, Christian

AU - Cardenas-Blanco, Arturo

AU - Pine, Kerrin

AU - Passamonti, Luca

AU - Loane, Clare

AU - Keuken, Max C

AU - Trujillo, Paula

AU - Lüsebrink, Falk

AU - Mattern, Hendrik

AU - Liu, Kathy Y

AU - Priovoulos, Nikos

AU - Fliessbach, Klaus

AU - Dahl, Martin J.

AU - Maaß, Anne

AU - Madelung, Christopher F

AU - Meder, David

AU - Ehrenberg, Alexander J

AU - Speck, Oliver

AU - Weiskopf, Nikolaus

AU - Dolan, Raymond

AU - Inglis, Ben

AU - Tosun, Duygu

AU - Morawski, Markus

AU - Zucca, Fabio A

AU - Siebner, Hartwig R.

AU - Mather, Mara

AU - Uludag, Kamil

AU - Heinsen, Helmut

AU - Poser, Benedikt A

AU - Howard, Robert

AU - Zecca, Luigi

AU - Rowe, James B.

AU - Grinberg, Lea T

AU - Jacobs, Heidi I L

AU - Düzel, Emrah

AU - Hämmerer, Dorothea

PY - 2019

Y1 - 2019

N2 - Pathological alterations to the locus coeruleus, the major source of noradrenaline in the brain, are histologically evident in early stages of neurodegenerative diseases. Novel MRI approaches now provide an opportunity to quantify structural features of the locus coeruleus in vivo during disease progression. In combination with neuropathological biomarkers, in vivo locus coeruleus imaging could help to understand the contribution of locus coeruleus neurodegeneration to clinical and pathological manifestations in Alzheimer's disease, atypical neurodegenerative dementias and Parkinson's disease. Moreover, as the functional sensitivity of the noradrenergic system is likely to change with disease progression, in vivo measures of locus coeruleus integrity could provide new pathophysiological insights into cognitive and behavioural symptoms. Locus coeruleus imaging also holds the promise to stratify patients into clinical trials according to noradrenergic dysfunction. In this article, we present a consensus on how non-invasive in vivo assessment of locus coeruleus integrity can be used for clinical research in neurodegenerative diseases. We outline the next steps for in vivo, post-mortem and clinical studies that can lay the groundwork to evaluate the potential of locus coeruleus imaging as a biomarker for neurodegenerative diseases.

AB - Pathological alterations to the locus coeruleus, the major source of noradrenaline in the brain, are histologically evident in early stages of neurodegenerative diseases. Novel MRI approaches now provide an opportunity to quantify structural features of the locus coeruleus in vivo during disease progression. In combination with neuropathological biomarkers, in vivo locus coeruleus imaging could help to understand the contribution of locus coeruleus neurodegeneration to clinical and pathological manifestations in Alzheimer's disease, atypical neurodegenerative dementias and Parkinson's disease. Moreover, as the functional sensitivity of the noradrenergic system is likely to change with disease progression, in vivo measures of locus coeruleus integrity could provide new pathophysiological insights into cognitive and behavioural symptoms. Locus coeruleus imaging also holds the promise to stratify patients into clinical trials according to noradrenergic dysfunction. In this article, we present a consensus on how non-invasive in vivo assessment of locus coeruleus integrity can be used for clinical research in neurodegenerative diseases. We outline the next steps for in vivo, post-mortem and clinical studies that can lay the groundwork to evaluate the potential of locus coeruleus imaging as a biomarker for neurodegenerative diseases.

U2 - 10.1093/brain/awz193

DO - 10.1093/brain/awz193

M3 - Journal article

C2 - 31327002

VL - 142

SP - 2558

EP - 2571

JO - Brain

JF - Brain

SN - 0006-8950

IS - 9

ER -

ID: 237654512